ConductScience.org, home

Paper626987

Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Dedrick RL and 3 others. Cancer Treat Rep, 1978. Cited by 742 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Papers, record 626987. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/626987

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
742
iCite
Relative citation ratio, by iCite
22.8
iCite
Revised in PubMed
2022-04-08
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dedrick RLR L
2Myers CEC E
3Bungay PMP M
4DeVita VT JrV T

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Ovarian NeoplasmsMajor topic
Ascitic Fluid
Cytarabine
Female
Humans
Injections, Intraperitoneal
Methotrexate
Models, Biological
Tissue Distribution

Source PubMed

Download CSV of topics

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00001569Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal CarcinomatosisBackgroundClinicalTrials.gov
NCT00004547Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and ChemotherapyBackgroundClinicalTrials.gov
NCT04885270Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian CancerBackgroundClinicalTrials.gov

Download CSV of trials

Cited by218

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 742 citations.

PMIDTitleJournalYearIn PapersSource
42449708Normothermic Intraperitoneal and Systemic Treatment (NIPS) Using Paclitaxel for Peritoneal Metastases from Gastrointestinal Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42449708PubMed
42310181Catheter based intraperitoneal chemotherapy using taxane for peritoneal metastases from gastric cancer: from bench to bedside-a narrative review.Gastric Cancer2026https://conductscience.org/library/papers/42310181PubMed
42240806Pressurised intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases: a scoping review of clinical evidence across emerging indications.Clin Transl Oncol2026https://conductscience.org/library/papers/42240806PubMed
42166134Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial.JAMA Oncol2026https://conductscience.org/library/papers/42166134PubMed
42001371Intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, oxaliplatin (FOLFOX) and nivolumab for gastric cancer with peritoneal metastasis: results from the IPLUS Phase II study.Gastric Cancer2026https://conductscience.org/library/papers/42001371PubMed
41937949A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer.Device2026https://conductscience.org/library/papers/41937949PubMed
41827699The New Era of Intraperitoneal Carboplatin in Ovarian Cancer: From Biological Rationale to Clinical Implementation.Cancers (Basel)2026https://conductscience.org/library/papers/41827699PubMed
41801509Pharmacokinetic and tissue distribution advantages of intraperitoneal oxaliplatin over systemic delivery: a swine model comparison of PIPAC and HPIPAC.Gastric Cancer2026https://conductscience.org/library/papers/41801509PubMed
41626069Considering homologous recombination deficiency status in HIPEC: could molecular testing someday drive "targeted" surgery?Gynecol Oncol Rep2025https://conductscience.org/library/papers/41626069PubMed
41595106
Intraperitoneal Chemotherapy Strategies in Pancreatic Ductal Adenocarcinoma: A Systematic Review of Hyperthermic Intraperitoneal Chemotherapy, Normothermic Intraperitoneal Chemotherapy, and Pressurized Intraperitoneal Aerosol Chemotherapy.
Cancers (Basel)2026https://conductscience.org/library/papers/41595106PubMed
41580538
Absolute Bioavailability of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC): Systemic Pharmacokinetics of the CRC-PIPAC-II Trial.
Ann Surg Oncol2026https://conductscience.org/library/papers/41580538PubMed
41393149Tertiary cytoreduction for recurrence of ovarian CANCER patients after intraperitoneal chemotherapy.Front Med (Lausanne)2025https://conductscience.org/library/papers/41393149PubMed
40855029Physiological Considerations and Delivery Strategies for Targeting Tumors Through Intraperitoneal Delivery.Pharm Res2025https://conductscience.org/library/papers/40855029PubMed
40301901Postoperative leukopenia after cytoreductive surgery and hypertherm intraperitoneal chemotherapy for colorectal carcinomatosis- causes and implication on outcomes in a population-based study.World J Surg Oncol2025https://conductscience.org/library/papers/40301901PubMed
40189674Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer.Ann Surg Oncol2025https://conductscience.org/library/papers/40189674PubMed
40016614Educational Review: Updates on Therapeutic Strategies for Gastric Cancer with Peritoneal Metastasis.Ann Surg Oncol2025https://conductscience.org/library/papers/40016614PubMed
39888579Innovative landscapes in intraperitoneal therapy of ovarian cancer.Drug Deliv Transl Res2025https://conductscience.org/library/papers/39888579PubMed
39439460Side-Effects on the Renal function of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.Int J Med Sci2024https://conductscience.org/library/papers/39439460PubMed
39199611Optimizing Timing of Intraperitoneal Chemotherapy to Enhance Intravenous Carboplatin Concentration.Cancers (Basel)2024https://conductscience.org/library/papers/39199611PubMed
38429574Hyperthermic pressurized intraperitoneal aerosol drug delivery system in a large animal model: a feasibility and safety study.Surg Endosc2024https://conductscience.org/library/papers/38429574PubMed

See all 218 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/626987

GET https://conductscience.org/api/papers/v1/626987/cited_by?page=2